News Releases
First Quarter Financial Results*
| Three Months Ended |
||||||||||||
| (Millions, except per share results) | 2016 | 2015 | Inc/(Dec) | |||||||||
| Net Revenue | $ | 1,117.0 | $ | 981.0 | 13.9 | % | ||||||
| Segment Profit* | 59.9 | 64.9 | (7.7 | )% | ||||||||
| Adjusted Net Income* | 19.4 | 24.4 | (20.5 | )% | ||||||||
| Net Income Attributable to Magellan | 13.2 | 7.3 | 80.8 | % | ||||||||
| Per Share Results: | ||||||||||||
| Adjusted Earnings per Share* | 0.79 | 0.94 | (16.0 | )% | ||||||||
| Earnings per Share | 0.54 | 0.28 | 92.9 | % | ||||||||
* Refer to the Basis of Presentation for a discussion of non-GAAP financial measures.
Variances for the three months ended
- The increase in revenue between periods resulted primarily from revenue from the 4D and TMG acquisitions, and the impact of new business and same store growth, which were partially offset by the loss of revenues associated with contract terminations.
- The decrease in segment profit is primarily due to the impact of contract terminations and net unfavorable year-over-year medical claims development. In addition, the current quarter includes a loss of approximately
$4.5 million from our Part D Plan, which we project to be timing-related as a result of benefit seasonality. These decreases were partially offset by the net impact of new business, net same store growth and higher earnings in our Pharmacy business. Included in segment profit this quarter is approximately$3.0 million of net favorable non-recurring items, mainly related to retroactive rate changes in the Healthcare segment. - The decrease in adjusted net income between periods was mainly due to the decrease in segment profit and a higher effective income tax rate in the current quarter.
- In addition to the items affecting adjusted net income explained above, the increase in net income between periods resulted primarily from a decrease in contingent consideration expense and stock compensation expense related to acquisitions.
"Our Pharmacy business began the year with solid performance, maintaining its positive momentum from 2015, and we continue to experience traction across all of our Pharmacy markets. In our Healthcare business, our results reflect modest progress in Magellan Complete Care of
Results and Outlook
"Relative to full year 2016, we are revising our guidance to reflect an increased new business projection, as well as the impact of recent share repurchase activity," said
"Compared to the first quarter of 2016, we expect an increased segment profit run rate for the remainder of the year due to continued care management progress in MCC of
Earnings Conference Call
Management will host a conference call at
About
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the company's performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after
Included in the tables issued with this press release are the reconciliations from non-GAAP measures to the corresponding GAAP measures.
Cautionary Statement
This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, 2016 guidance, expected increased segment profit run rate for the remainder of 2016, growth opportunities and strategy. These statements are based on management's analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "may," "should," "could," "estimate," "intend" and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company's customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company's risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||||||||
| (In thousands, except per share amounts) | |||||||||
| Three Months Ended |
|||||||||
| 2015 |
2016 (1) |
||||||||
| (unaudited) | (unaudited) | ||||||||
| Net revenue: | |||||||||
| Managed care and other | $ | 748,650 | $ | 676,461 | |||||
| PBM and dispensing | 232,318 | 440,561 | |||||||
| Total net revenue | 980,968 | 1,117,022 | |||||||
| Costs and expenses: | |||||||||
| Cost of care | 522,328 | 457,631 | |||||||
| Cost of goods sold | 218,207 | 415,459 | |||||||
| Direct service costs and other operating expenses (2)(3) | 204,450 | 192,456 | |||||||
| Depreciation and amortization | 23,496 | 25,007 | |||||||
| Interest expense | 1,626 | 1,748 | |||||||
| Interest income and other income | (466 | ) | (683 | ) | |||||
| Total costs and expenses | 969,641 | 1,091,618 | |||||||
| Income before income taxes | 11,327 | 25,404 | |||||||
| Provision for income taxes | 4,133 | 12,013 | |||||||
| Net income | 7,194 | 13,391 | |||||||
| Less: net (loss) income attributable to non-controlling interest | (94 | ) | 154 | ||||||
| Net income attributable to |
$ | 7,288 | $ | 13,237 | |||||
| Weighted average number of common shares outstanding — basic | 25,319 | 23,631 | |||||||
| Weighted average number of common shares outstanding — diluted | 26,399 | 24,495 | |||||||
| Net income per common share attributable to |
$ | 0.29 | $ | 0.56 | |||||
| Net income per common share attributable to |
$ | 0.28 | $ | 0.54 | |||||
| Net income | $ | 7,194 | $ | 13,391 | |||||
| Other comprehensive income: | |||||||||
| Unrealized losses on available-for-sale securities (4) | 69 | 238 | |||||||
| Comprehensive income | 7,263 | 13,629 | |||||||
| Less: comprehensive (loss) income attributable to non-controlling interest | (94 | ) | 154 | ||||||
| Comprehensive income attributable to |
$ | 7,357 | $ | 13,475 | |||||
|
(1) |
For a more detailed discussion of |
||
|
(2) |
Includes stock compensation expense of |
||
|
(3) |
Includes changes in fair value of contingent consideration of |
||
|
(4) |
Net of income tax provision of |
| NON-GAAP MEASURES | |||||||||
| (In thousands, except per share amounts) | |||||||||
| Three Months Ended |
|||||||||
| 2015 |
2016 (1) |
||||||||
| (unaudited) | (unaudited) | ||||||||
| Adjusted net income | $ | 24,384 | $ | 19,429 | |||||
| Adjusted for acquisitions starting in 2013 | |||||||||
| Stock compensation expense relating to acquisitions | (8,338 | ) | (4,556 | ) | |||||
| Changes in fair value of contingent consideration | (14,969 | ) | 266 | ||||||
| Amortization of acquired intangibles | (4,383 | ) | (5,780 | ) | |||||
| Tax impact | 10,594 | 3,878 | |||||||
| Net income attributable to |
$ | 7,288 | $ | 13,237 | |||||
| Adjusted EPS | $ | 0.94 | $ | 0.79 | |||||
| Adjusted for acquisitions starting in 2013 | |||||||||
| Stock compensation expense relating to acquisitions | (0.32 | ) | (0.19 | ) | |||||
| Changes in fair value of contingent consideration | (0.57 | ) | 0.01 | ||||||
| Amortization of acquired intangibles | (0.17 | ) | (0.23 | ) | |||||
| Tax impact | 0.40 | 0.16 | |||||||
| Net income per common share attributable to |
$ | 0.28 | $ | 0.54 | |||||
|
(1) |
The Company's Quarterly Report on Form 10-Q for the three months ended |
||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (In thousands) | |||||||||
| Three Months Ended |
|||||||||
| 2015 |
2016 (1) |
||||||||
| (unaudited) | (unaudited) | ||||||||
| Cash flows from operating activities: | |||||||||
| Net income | $ | 7,194 | $ | 13,391 | |||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||||
| Depreciation and amortization | 23,496 | 25,007 | |||||||
| Non-cash interest expense | 99 | 102 | |||||||
| Non-cash stock compensation expense | 13,901 | 8,887 | |||||||
| Non-cash income tax benefit | (2,263 | ) | (538 | ) | |||||
| Non-cash amortization on investments | 1,539 | 1,844 | |||||||
|
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses: |
|||||||||
| Restricted cash (2) | 9,739 | 53,322 | |||||||
| Accounts receivable, net | 1,425 | (13,538 | ) | ||||||
| Pharmaceutical inventory | 4,770 | (5,121 | ) | ||||||
| Other assets | (27,219 | ) | (35,839 | ) | |||||
| Accounts payable and accrued liabilities | (25,887 | ) | 11,023 | ||||||
| Medical claims payable and other medical liabilities | 23,663 | (38,292 | ) | ||||||
| Contingent consideration | 14,969 | 734 | |||||||
| Tax contingencies | (787 | ) | 289 | ||||||
| Deferred credits and other long-term liabilities | (480 | ) | (227 | ) | |||||
| Other | (3 | ) | 34 | ||||||
| Net cash provided by operating activities | 44,156 | 21,078 | |||||||
| Cash flows from investing activities: | |||||||||
| Capital expenditures | (21,396 | ) | (15,611 | ) | |||||
| Acquisitions and investments in businesses, net of cash acquired | (13,640 | ) | (16,214 | ) | |||||
| Purchase of investments | (128,851 | ) | (157,020 | ) | |||||
| Maturity of investments | 92,499 | 144,902 | |||||||
| Net cash used in investing activities | (71,388 | ) | (43,943 | ) | |||||
| Cash flows from financing activities: | |||||||||
| Payments to acquire treasury stock | (32,112 | ) | (7,992 | ) | |||||
| Proceeds from exercise of stock options and warrants | 36,900 | 7,784 | |||||||
| Payments on long-term debt and capital lease obligations | (3,662 | ) | (4,154 | ) | |||||
| Payments on contingent consideration | - | (2,000 | ) | ||||||
| Tax benefit from exercise of stock options and vesting of stock awards | 2,961 | 383 | |||||||
| Other | (807 | ) | (72 | ) | |||||
| Net cash provided by (used in) financing activities | 3,280 | (6,051 | ) | ||||||
| Net decrease in cash and cash equivalents | (23,952 | ) | (28,916 | ) | |||||
| Cash and cash equivalents at beginning of period | 255,303 | 115,432 | |||||||
| Cash and cash equivalents at end of period | $ | 231,351 | $ | 86,516 | |||||
|
(1) |
The Company's Quarterly Report on Form 10-Q for the three months ended |
||
|
(2) |
Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the three months ended |
||
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | |||||||||
| (In thousands) | |||||||||
| Three Months Ended |
|||||||||
| 2015 |
2016 (1) |
||||||||
| (unaudited) | (unaudited) | ||||||||
|
Healthcare |
|||||||||
| Managed care and other net revenue | $ | 699,593 | $ | 618,928 | |||||
| Cost of care | 522,333 | 457,631 | |||||||
| Direct service costs and other | 112,720 | 109,300 | |||||||
| Stock compensation expense (2) | (3,188 | ) | (2,019 | ) | |||||
| Changes in fair value of contingent consideration (2) | (100 | ) | 320 | ||||||
| Non-controlling interest - segment profit (loss) (3) | (120 | ) | 169 | ||||||
| Healthcare segment profit | 67,948 | 53,527 | |||||||
| Allocated corporate costs (4) | 15,748 | 16,317 | |||||||
| Healthcare segment profit after corporate allocations | 52,200 | 37,210 | |||||||
|
Pharmacy Management |
|||||||||
| Managed care and other net revenue | 49,068 | 57,577 | |||||||
| PBM and dispensing revenue | 258,793 | 470,234 | |||||||
| Cost of care | (5 | ) | - | ||||||
| Cost of goods sold | 243,538 | 443,949 | |||||||
| Direct service costs and other | 64,097 | 56,631 | |||||||
| Stock compensation expense (2) | (9,405 | ) | (5,422 | ) | |||||
| Changes in fair value of contingent consideration (2) | (14,869 | ) | (54 | ) | |||||
| Pharmacy Management segment profit | 24,505 | 32,707 | |||||||
| Allocated corporate costs (4) | 4,136 | 4,210 | |||||||
| Pharmacy Management segment profit after corporate allocations | 20,369 | 28,497 | |||||||
|
Corporate and Other (including eliminations) (5) |
|||||||||
| Managed care and other net revenue eliminations | (11 | ) | (44 | ) | |||||
| PBM and dispensing revenue eliminations | (26,475 | ) | (29,673 | ) | |||||
| Cost of goods sold eliminations | (25,331 | ) | (28,490 | ) | |||||
| Corporate and eliminations | 27,633 | 26,525 | |||||||
| Stock compensation expense (2) | (1,308 | ) | (1,446 | ) | |||||
| Non-controlling interest - segment profit (loss) (3) | 26 | (4 | ) | ||||||
| Corporate and Other (including eliminations) | (27,506 | ) | (26,302 | ) | |||||
| Allocated corporate costs (4) | (19,884 | ) | (20,527 | ) | |||||
| Corporate costs and eliminations after corporate allocations | (7,622 | ) | (5,775 | ) | |||||
|
Consolidated |
|||||||||
| Managed care and other net revenue | 748,650 | 676,461 | |||||||
| PBM and dispensing revenue | 232,318 | 440,561 | |||||||
| Cost of care | 522,328 | 457,631 | |||||||
| Cost of goods sold | 218,207 | 415,459 | |||||||
| Direct service costs and other | 204,450 | 192,456 | |||||||
| Stock compensation expense (2) | (13,901 | ) | (8,887 | ) | |||||
| Changes in fair value of contingent consideration (2) | (14,969 | ) | 266 | ||||||
| Non-controlling interest - segment profit (loss) (3) | (94 | ) | 165 | ||||||
| Consolidated segment profit | $ | 64,947 | $ | 59,932 | |||||
|
Reconciliation of segment profit to income before income taxes: |
|||||||||
| Segment profit | $ | 64,947 | $ | 59,932 | |||||
| Stock compensation expense | (13,901 | ) | (8,887 | ) | |||||
| Changes in fair value of contingent consideration | (14,969 | ) | 266 | ||||||
| Non-controlling interest segment profit (loss) | (94 | ) | 165 | ||||||
| Depreciation and amortization | (23,496 | ) | (25,007 | ) | |||||
| Interest expense | (1,626 | ) | (1,748 | ) | |||||
| Interest and other income | 466 | 683 | |||||||
| Income before income taxes | $ | 11,327 | $ | 25,404 | |||||
|
(1) |
The Company's Quarterly Report on Form 10-Q for the three months ended |
||
|
(2) |
Stock compensation expense, as well as changes in the fair value of contingent consideration recorded in relation to the acquisitions, are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit. |
||
|
(3) |
The non-controlling portion of AlphaCare's segment profit (loss) is excluded from the computation of segment profit. |
||
|
(4) |
Effective |
||
|
(5) |
Healthcare subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Healthcare's customers. In addition, Pharmacy Management provides pharmacy benefits management for the Company's employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated. |
||
View source version on businesswire.com: http://www.businesswire.com/news/home/20160505005425/en/
Media Contact:
cefjohnson@magellanhealth.com
or
Investor Contact:
rshapiro@magellanhealth.com
Source:
News Provided by Acquire Media
